Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients.
Delhorme JB, Ohayon J, Gouy S, Averous G, Genestie C, Gaichies L, Glehen O, Guilloit JM, Pezet D, Quenet F, Ferron G, Brigand C, Morice P, Honoré C; French Network for Rare Peritoneal Malignancies (RENAPE). Delhorme JB, et al. Among authors: genestie c. Eur J Surg Oncol. 2020 May;46(5):862-867. doi: 10.1016/j.ejso.2019.12.005. Epub 2019 Dec 9. Eur J Surg Oncol. 2020. PMID: 31902591
Clinical transfer of AGuIX®-based radiation treatments for locally advanced cervical cancer: MR quantification and in vitro insights in the NANOCOL clinical trial framework.
Maury P, Mondini M, Chargari C, Darricau A, Shahin M, Ammari S, Bockel S, Genestie C, Wu TD, Lux F, Tillement O, Lacombe S, Deutsch E, Robert C, Porcel E. Maury P, et al. Among authors: genestie c. Nanomedicine. 2023 Jun;50:102676. doi: 10.1016/j.nano.2023.102676. Epub 2023 Apr 20. Nanomedicine. 2023. PMID: 37084803
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor.
Ducarouge B, Redavid AR, Victoor C, Chira R, Fonseca A, Hervieu M, Bergé R, Lengrand J, Vieugué P, Neves D, Goddard I, Richaud M, Laval PA, Rama N, Goldschneider D, Paradisi A, Gourdin N, Chabaud S, Treilleux I, Gadot N, Ray-Coquard I, Depil S, Decaudin D, Némati F, Marangoni E, Mery-Lamarche E, Génestie C, Tabone-Eglinger S, Devouassoux-Shisheboran M, Moore KJ, Gibert B, Mehlen P, Bernet A. Ducarouge B, et al. Among authors: genestie c. Cell Death Differ. 2023 Oct;30(10):2201-2212. doi: 10.1038/s41418-023-01209-x. Epub 2023 Aug 26. Cell Death Differ. 2023. PMID: 37633969
Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
Pautier P, Genestie C, Fizazi K, Morice P, Mottet C, Haie-Meder C, Le Cesne A, Lhommé C. Pautier P, et al. Among authors: genestie c. Int J Gynecol Cancer. 2002 Nov-Dec;12(6):749-54. doi: 10.1046/j.1525-1438.2002.01144.x. Int J Gynecol Cancer. 2002. PMID: 12445254
Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique.
Querleu D, Planchamp F, Narducci F, Morice P, Joly F, Genestie C, Haie-Meder C, Thomas L, Quénel-Tueux N, Daraï E, Dorangeon PH, Marret H, Taïeb S, Mazeau-Woynar V; Institut National du Cancer; Societe Francaise d'Oncologie Gynecologique. Querleu D, et al. Among authors: genestie c. Int J Gynecol Cancer. 2011 Jul;21(5):945-50. doi: 10.1097/IGC.0b013e31821bd473. Int J Gynecol Cancer. 2011. PMID: 21697683
[Initial management of advanced ovarian cancer: What radiological, pathological and surgical information are important for optimal therapeutic strategy?].
Heudel PE, Selle F, Morice P, Rouzier R, Taieb S, Devouassoux-Shisheboran M, Genestie C, Balleyguier C, Ray-Coquard I. Heudel PE, et al. Among authors: genestie c. Bull Cancer. 2015 Sep;102(9):772-9. doi: 10.1016/j.bulcan.2015.04.011. Epub 2015 May 28. Bull Cancer. 2015. PMID: 26028492 Review. French.
155 results